Stocks · News reference
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
American LLC ("NYSE American") that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide (the "Company
Read original at benzingaFiled: 2026-08-14 AccNo: 0001213900-26-090232 Size: 259 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarActinium Pharmaceuticals (AMEX:ATNM) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $(0.21) by 523.81 percent. This is a 504.55 percent increase over losses of $(0.22) per
Read original at benzinga